Targovax granted Patents for ONCOS-102 in combination with chemotherapy in China and Japan
Oslo, 17 January 2022: Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announce that patents no CN108495934 and JP6974350 have been granted by the Chinese and Japanese Patent Offices, respectively. The patents cover the use of ONCOS-102 in combination with chemotherapy in malignant mesothelioma.
Andreas Berg Storsve, VP Business Development and IP at Targovax, said: “We are delighted that these patents have been granted, further strengthening Targovax’s intellectual property portfolio. The 30-month data from our ONCOS-102 trial in mesothelioma demonstrate very strong survival outcomes in the first-line setting, and this remains an area of high medical need. Securing these patents protects our innovative oncolytic immunotherapy platform and strengthens our future market position in the major Asian markets.”
Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system. In December 2021, the 30-month follow-up in the malignant pleural mesothelioma (MPM) trial showed 25.0 months median overall survival (mOS) for patients in first-line treatment with ONCOS-102 plus chemotherapy, which is very encouraging in this patient population with poor prognosis.
The US FDA granted ONCOS-102 Fast Track designation for MPM in February 2021 based on the encouraging pre-clinical and clinical data package. ONCOS-102 also has orphan drug designation for MPM with both the US FDA and the European Medicines Agency.
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax aims to unlock greater clinical benefits in cancer patients by deploying its multifunctional platforms to target key immune regulators and oncogenic drivers. Targovax’s focus is to “activate the patient’s immune system to fight cancer”, thus extending and transforming the lives of cancer patients. Targovax’s pipeline aims at different cancer indications, including melanoma, mesothelioma and colorectal cancer. The company’s product candidates are designed to harness the patient’s own immune system to fight the cancer, whilst also delivering a favorable safety and tolerability profile.
Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. On the back of very encouraging clinical data in several indications, both in monotherapy and in multiple combinations, the next development steps for ONCOS-102 will be to further improve responses in melanoma patients resistant to or poorly responsive to current standard of care.